Neurodevelopmental assessment tools serve as indispensable instruments utilized by healthcare professionals to meticulously evaluate the cognitive, motor, language, and social-emotional development of infants, children, and adolescents. These tools furnish critical insights into a child's developmental trajectory, aiding in the detection of any potential delays or disorders warranting intervention. Encompassing various domains such as gross and fine motor skills, language proficiency, cognitive function, social interaction, and adaptive behavior, these assessments are tailored to different age groups and developmental stages. Examples of widely employed neurodevelopmental assessment tools include the Bayley Scales of Infant and Toddler Development, which evaluates cognitive, motor, and language skills in children up to 42 months old, and the Denver Developmental Screening Test, designed to screen for developmental delays in children from birth to six years of age. Additionally, the Wechsler Intelligence Scale for Children serves to gauge cognitive abilities in children and adolescents aged 6 to 16 years. Administered by a range of healthcare professionals including pediatricians, psychologists, occupational therapists, speech-language pathologists, and developmental specialists, these assessments play a pivotal role in identifying developmental disorders like autism spectrum disorder, attention deficit hyperactivity disorder, intellectual disabilities, or cerebral palsy. Early intervention facilitated by neurodevelopmental assessment tools ensures timely management, optimizing outcomes for children grappling with neurodevelopmental challenges.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States